Skip to main content
Premium Trial:

Request an Annual Quote

Illumina to Place BeadLab System at CHOP; Deal Could Exceed $25M

NEW YORK, June 7 (GenomeWeb News) - Illumina will provide The Children's Hospital of Philadelphia with its BeadLab genotyping system, the company said today.


The hospital will house the system at its new Center for Applied Genomics and will provide a core capability for CHOP's research goal of ultimately genotyping over 100,000 children with a focus on asthma, obesity, diabetes, and cancer, Illumina said.


According to the company, the initial value of the agreement, which includes arrays and reagents for the first 30,000 samples, is expected to exceed $25 million.


CHOP said that it plans to first conduct whole-genome genotyping using Sentrix HumanHap550 BeadChips, though subsequent phases of its research will use Illumina arrays and reagents to study focused sets of SNPs thought to be implicated in disease cause and progression.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.